MAY 19, 2015
Glytec Presents Several Research Studies at the AACE 24th Annual Scientific and Clinical Congress
Leading industry experts present the benefits of automated glucose management for both IV and subcutaneous insulin dosing.
Waltham, MA — Glytec, the pioneer and leader in providing innovative glucose management software solutions central to effective diabetes management, today announced that several abstracts featuring the company’s eGlycemic Management System® (eGMS®) were selected as poster presentations at the American Association of Clinical Endocrinologists (AACE) 24th Annual Scientific and Clinical Congress, which took place from May 13-17th in Nashville, Tennessee.
“Each year the AACE brings together the best and brightest in endocrinology and we were honored to be able to present several clinical studies at this year’s meeting,” said Melanie Mabrey, Vice President of Clinical Practice at Glytec. “Our latest round of studies highlight the benefits of integrated, advanced technology in titrating IV and SubQ insulin (as well as the transition from one to the other) across a wide variety of patients compared to traditional protocols; along with the ability to easily identify and intervene in patients with hyperglycemia early in the admission.”
The AACE 24th Annual Scientific and Clinical Congress is structured to provide relevant information for practicing endocrinologists, focusing on best practices for the diagnosis and management of endocrine diseases.
To showcase proven results of improved insulin management using Glytec’s eGMS®, the following scientific posters were presented at the conference by industry thought leaders, including: Joseph Aloi, MD, Chief, Section on Endocrinology and Metabolism at Wake Forest University Medical Center; Paul Chidester, MD, Vice President of Medical Affairs at Sentara Healthcare; Jagdeesh Ullal, MD, MS, CCD, ECNU, FACE, FACP, Assistant Professor, EVMS Strelitz Diabetes Center; Melanie Mabrey, DNP, ACNP-BC, BC-ADM, FAANP, Vice President of Clinical Practice at Glytec; Raymie McFarland, PT, SSCGB, Vice President of Quality Initiatives at Glytec; Amy Henderson, RN, BSN, Clinical Solutions Consultant at Glytec; and Robby Booth, Senior Vice President of R&D at Glytec.
- eGlycemic Management System Safely Achieves Prescribed Glycemic Target with Low Incidence of Hypoglycemia in Patients with Acute Myocardial Infarction in the Hospital — This study showcases the effectiveness of using Glytec’s eGMS® with GlucoSurveillance to identify patients with hyperglycemia and AMI. Furthermore, using the eGMS® to initiate and manage insulin helped patients achieve target glucose levels at a higher percentage than standard paper order sets with less hypoglycemia.
- eGlycemic Management System Safely Maintains Glycemic Targets with a Low Incidence of Hypoglycemia for Non-Diabetic CV Surgical Patients in the Inpatient Setting — This poster details that when leveraging Glytec’s eGMS®, both IV and subcutaneous insulin regimens are safe for non-diabetic cardiovascular surgery patients, resulting in no occurrence of severe hypoglycemia.
- eGlycemic Management System Safely Achieves Multiple Prescribed Glycemic Targets with Rare Hypoglycemia for Geriatric Inpatients — Results of this study showcase overall very low rates of mild hypoglycemia or severe hypoglycemia in geriatric patients during treatment, leveraging Glytec’s eGMS®.
- eGlycemic Management System Provides Safe and Effective Meal Coverage for Critical Care and Surgery Patients Managed with IV Insulin in the Hospital — Results from this study suggest that Glytec’s eGMS® can safely maintain prescribed glucose targets with very minimal risk of hypoglycemia for critical care and surgery patients consuming carbohydrates and requiring IV insulin therapy.
“These studies demonstrate the flexibility, effectiveness and safety of Glytec’s eGlycemic Management System,” said Chidester. “With various populations and modules, we consistently have observed excellent glycemic control in our health system.”